• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hematology: Thalidomide maintenance in multiple myeloma.

作者信息

Laubach Jacob P, Richardson Paul G, Anderson Kenneth C

出版信息

Nat Rev Clin Oncol. 2009 Oct;6(10):565-6. doi: 10.1038/nrclinonc.2009.131.

DOI:10.1038/nrclinonc.2009.131
PMID:19787000
Abstract
摘要

相似文献

1
Hematology: Thalidomide maintenance in multiple myeloma.
Nat Rev Clin Oncol. 2009 Oct;6(10):565-6. doi: 10.1038/nrclinonc.2009.131.
2
Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma.沙利度胺联合长春新碱/多柔比星和地塞米松减量方案诱导缓解后自体造血干细胞移植治疗多发性骨髓瘤。
Invest New Drugs. 2011 Feb;29(1):175-81. doi: 10.1007/s10637-009-9343-4. Epub 2009 Oct 13.
3
Treatment of multiple myeloma: 2009 update.多发性骨髓瘤的治疗：2009年更新
Prescrire Int. 2009 Dec;18(104):263-6.
4
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.骨髓瘤诱导治疗的移植后结局：沙利度胺与地塞米松对比多柔比星、长春新碱及地塞米松用于高剂量美法仑联合自体干细胞支持治疗之前
Am J Hematol. 2007 Dec;82(12):1071-5. doi: 10.1002/ajh.21038.
5
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.硼替佐米为基础与非硼替佐米为基础的诱导治疗在前未经治疗多发性骨髓瘤患者自体造血干细胞移植前：III 期随机对照试验的荟萃分析。
J Clin Oncol. 2013 Sep 10;31(26):3279-87. doi: 10.1200/JCO.2012.48.4626. Epub 2013 Jul 29.
6
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.沙利度胺、长春新碱、脂质体阿霉素和地塞米松联合用于多发性骨髓瘤的初始治疗（T-VAD多柔比星脂质体方案）：一项II期多中心研究。
Ann Oncol. 2004 Jan;15(1):134-8. doi: 10.1093/annonc/mdh026.
7
Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.沙利度胺与地塞米松：多发性骨髓瘤初始治疗的新护理标准
J Clin Oncol. 2006 Jan 20;24(3):334-6. doi: 10.1200/JCO.2005.03.8851. Epub 2005 Dec 19.
8
Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.聚乙二醇化脂质体阿霉素、长春新碱、低剂量地塞米松和沙利度胺用于新诊断及复发难治性多发性骨髓瘤的2期研究
Mayo Clin Proc. 2006 Jul;81(7):889-95. doi: 10.4065/81.7.889.
9
A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma.
Leuk Lymphoma. 2005 Jun;46(6):945-7. doi: 10.1080/10428190500057684.
10
Lenalidomide plus dexamethasone in multiple myeloma.来那度胺联合地塞米松治疗多发性骨髓瘤
Lancet Oncol. 2018 Jan;19(1):e12. doi: 10.1016/S1470-2045(17)30894-X. Epub 2017 Nov 23.

引用本文的文献

1
Protective Effects of Rifampicin and Its Analog Rifampicin Quinone in a Mouse Model of Obesity-Induced Type 2 Diabetes.利福平及其类似物醌式利福平在肥胖诱导的2型糖尿病小鼠模型中的保护作用
ACS Pharmacol Transl Sci. 2023 Jan 12;6(2):253-269. doi: 10.1021/acsptsci.2c00082. eCollection 2023 Feb 10.
2
Artificial intelligence in COVID-19 drug repurposing.人工智能在新冠病毒药物再利用中的应用。
Lancet Digit Health. 2020 Dec;2(12):e667-e676. doi: 10.1016/S2589-7500(20)30192-8. Epub 2020 Sep 18.
3
Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study.

本文引用的文献

1
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.低剂量沙利度胺与泼尼松龙的巩固治疗可延长接受单次自体干细胞移植手术的多发性骨髓瘤患者的生存期。
J Clin Oncol. 2009 Apr 10;27(11):1788-93. doi: 10.1200/JCO.2008.18.8573. Epub 2009 Mar 9.
2
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.沙利度胺维持治疗可改善多发性骨髓瘤患者的生存率。
Blood. 2006 Nov 15;108(10):3289-94. doi: 10.1182/blood-2006-05-022962. Epub 2006 Jul 27.
3
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
干扰素-α/粒细胞-巨噬细胞集落刺激因子联合作为自体造血干细胞移植（ASCT）后多发性骨髓瘤患者的维持治疗：一项前瞻性 II 期研究。
Clin Med Insights Oncol. 2010 Nov 16;4:117-25. doi: 10.4137/CMO.S6161.
口服美法仑和泼尼松化疗加沙利度胺与单纯美法仑和泼尼松用于老年多发性骨髓瘤患者的比较：随机对照试验
Lancet. 2006 Mar 11;367(9513):825-31. doi: 10.1016/S0140-6736(06)68338-4.
4
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.沙利度胺与造血干细胞移植治疗多发性骨髓瘤
N Engl J Med. 2006 Mar 9;354(10):1021-30. doi: 10.1056/NEJMoa053583.
5
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.沙利度胺联合地塞米松与单独使用地塞米松治疗新诊断多发性骨髓瘤的III期临床试验：一项由东部肿瘤协作组协调的临床试验
J Clin Oncol. 2006 Jan 20;24(3):431-6. doi: 10.1200/JCO.2005.03.0221. Epub 2005 Dec 19.
6
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant.
Clin Cancer Res. 2004 Dec 15;10(24):8170-6. doi: 10.1158/1078-0432.CCR-04-1106.
7
Antitumor activity of thalidomide in refractory multiple myeloma.沙利度胺在难治性多发性骨髓瘤中的抗肿瘤活性。
N Engl J Med. 1999 Nov 18;341(21):1565-71. doi: 10.1056/NEJM199911183412102.
8
Bone marrow angiogenesis and progression in multiple myeloma.多发性骨髓瘤中的骨髓血管生成与进展
Br J Haematol. 1994 Jul;87(3):503-8. doi: 10.1111/j.1365-2141.1994.tb08304.x.
9
Thalidomide is an inhibitor of angiogenesis.沙利度胺是一种血管生成抑制剂。
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5. doi: 10.1073/pnas.91.9.4082.